دورية أكاديمية
[Ultra high-risk refractory multiple myeloma with a complex karyotype including t(14;19)].
| العنوان: | [Ultra high-risk refractory multiple myeloma with a complex karyotype including t(14;19)]. |
|---|---|
| المؤلفون: | Aoki G; Department of Internal Medicine, Fukui-ken Saiseikai Hospital., Sawazaki A; Department of Internal Medicine, Fukui-ken Saiseikai Hospital., Notsumata K; Department of Internal Medicine, Fukui-ken Saiseikai Hospital., Ushiogi Y; Department of Internal Medicine, Fukui-ken Saiseikai Hospital., Okafuji K; Department of Internal Medicine, Fukui-ken Saiseikai Hospital., Toya D; Department of Internal Medicine, Fukui-ken Saiseikai Hospital. |
| المصدر: | [Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2020; Vol. 61 (3), pp. 240-244. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | Japanese |
| بيانات الدورية: | Publisher: Japan Society Of Clinical Hematology Country of Publication: Japan NLM ID: 2984782R Publication Model: Print Cited Medium: Print ISSN: 0485-1439 (Print) Linking ISSN: 04851439 NLM ISO Abbreviation: Rinsho Ketsueki Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tokyo : Japan Society Of Clinical Hematology Original Publication: Tokyo, Rinsho Ketsueki Kondankai. |
| مواضيع طبية MeSH: | Multiple Myeloma*/genetics, Aged ; Antineoplastic Combined Chemotherapy Protocols ; Bortezomib ; Chromosomes, Human, Pair 14 ; Chromosomes, Human, Pair 19 ; Dexamethasone ; Humans ; Karyotype ; Male ; Thalidomide |
| مستخلص: | A 78-year-old man was hospitalized because of rapid progression of chronic renal failure and diagnosed with multiple myeloma (MM) IgG-λ type ISS-III R-ISS-II with complex karyotype including t(14;19). Even after receiving bortezomib-based regimens, his renal failure progressed. He became dependent on dialysis, which was required three times a week. After introducing the daratumumab (DARA)-based regimen, his renal function improved, the frequency of dialysis decreased to twice a week, and the free light chain (FLC) ratio also improved. However, his myeloma eventually followed a refractory course; therefore, pomalidomide (POM)-dexamethasone (Pd) regimen was administered. Pd regimen had a marked effect and normalized the FLC ratio after three courses of the treatment. However, his myeloma reprogressed with multiple extramedullary masses and he became del(17p) positive; eventually, he died on the 470th day of disease. MM with t(14;19) is rare and has a poor prognosis with a highly aggressive course; however, early introduction of DARA or POM may provide long-term response. |
| فهرسة مساهمة: | Keywords: Daratumumab; Multiple myeloma; Pomalidomide; t(14;19) |
| المشرفين على المادة: | 4Z8R6ORS6L (Thalidomide) 69G8BD63PP (Bortezomib) 7S5I7G3JQL (Dexamethasone) |
| تواريخ الأحداث: | Date Created: 20200401 Date Completed: 20200512 Latest Revision: 20200512 |
| رمز التحديث: | 20240628 |
| DOI: | 10.11406/rinketsu.61.240 |
| PMID: | 32224584 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0485-1439 |
|---|---|
| DOI: | 10.11406/rinketsu.61.240 |